The question
Melanotan II safety claims need more than a before-and-after tanning photograph. Published case reports describe serious events after use, while FDA identifies potential risks in its compounding safety assessment. Such reports are important signals, but they cannot supply a reliable percentage risk for a person considering a product. FDA safety assessment.
One documented event behind the warnings
A 2021 clinical report described acute ischemic priapism after Melanotan II injection. Initial treatment did not resolve the prolonged erection, and the patient required surgical management. This was a documented clinical case, not a controlled experiment measuring how often the event occurs. Original case report.
A different report described systemic toxicity and rhabdomyolysis after use of an internet-purchased preparation. The authors reported the clinical course of one patient; that does not establish a typical response among all users. Original toxicology report.
These examples matter because the harm being described goes beyond an unwanted cosmetic result. They also demonstrate why a safety account should use the actual published event rather than an invented patient story or an anecdote with unverifiable details.
Why case reports cannot give you a risk percentage
To estimate frequency, researchers need to know how many people were exposed, which product they received, how exposure was documented, and how consistently events were sought. A collection of case reports does not provide that denominator. Reporting can also be uneven: some events reach clinicians and journals, while others do not.
Timing alone is not conclusive proof of causation. Investigators must consider other exposures, underlying conditions and uncertainty about the preparation. Yet the absence of a precise causal estimate is not a reason to dismiss a serious event. A signal can justify concern and further investigation before its frequency is known.
Be precise about the cancer question
FDA's current page lists melanoma among serious events discussed in published reports, alongside neurological and other systemic events. The list is not a controlled estimate of a causal melanoma risk. FDA assessment, checked September 26, 2026.
“Definitely causes cancer” and “no proven risk, therefore safe” both go further than that evidence. A careful article should preserve the distinction between a reported association, a plausible concern and a quantified causal effect.
US product status does not come from a related medicine
FDA has explicitly described Melanotan II as an unapproved injectable tanning product. FDA enforcement record. The separate prescription product Scenesse has a defined medical indication involving afamelanotide; its label does not establish approval of Melanotan II. Scenesse label.
For a reader, the practical conclusion is that a visible effect cannot validate a product's safety or approval. Our peptide introduction provides background.
Related reading
Continue with afamelanotide’s separate approved use.
Sources & further reading
Research context last reviewed September 26, 2026. Last updated October 6, 2026. Educational reading, not individual medical advice. How this article was prepared.
